<DOC>
	<DOCNO>NCT02242734</DOCNO>
	<brief_summary>Determine influence hepatic impairment pharmacokinetics metabolism Hydrocodone Bitartrate Extended-Release ( HC-ER ) 20 mg capsule</brief_summary>
	<brief_title>Pharmacokinetics Metabolism Hydrocodone Bitartrate Controlled-Release ( HC-CR ) Subjects With Hepatic Impairment</brief_title>
	<detailed_description>Pharmacokinetics relative bioavailability hydrocodone metabolite fast condition</detailed_description>
	<mesh_term>Liver Diseases</mesh_term>
	<mesh_term>Hydrocodone</mesh_term>
	<criteria>1 . All hepaticallyimpaired subject must meet follow inclusion criterion enrol study : 2 . Male nonpregnant , nonlactating female . Subjects age 1880 year , inclusive . 3 . Subjects must clinical diagnosis chronic hepatic impairment duration least 6 month classify mild moderate per ChildPugh classification . 4 . Hepatic insufficiency stable acute episode illness within previous 2 month due deterioration hepatic function due etiology . 5 . Female subject childbearing potential include tubal ligation surgery exclude menstrual period minimum 2 year , negative pregnancy test Screening Day 1 visit , consent use medicallyacceptable method contraception throughout entire study period 1 week study complete . Medically acceptable method contraception include limited abstinence , birth control pills patch , vaginal ring , diaphragm vaginal spermicide , Intrauterine Device , progestin implant injection ( use consistently 3 month prior study dose ) . 6 . Subjects voluntarily provide write informed consent . 7 . Subjects , Investigator 's opinion , able complete study procedure All healthy control subject must meet hepatic subject inclusion criterion outline exception Inclusion Criteria 3 &amp; 4 substitute follow enrol study : Must match age ( ±10 year ) Body Mass Index ( BMI ) ( ± 10 % BMI ) consideration race gender subject hepatic impairment . Were medically healthy clinically significant abnormality laboratory profile deem Investigator . 1 . Women pregnant breastfeed 2 . Any clinically significant condition would , opinion Investigator , preclude study participation 3 . Uncontrolled blood pressure , i.e. , subject sit systolic blood pressure 180 mmHg 90 mmHg , and/or sit diastolic blood pressure 120 mmHg 50 mmHg Screening . 4 . Body Mass Index ( BMI ) &gt; 40 kg/m2 . 5 . Known allergy hypersensitivity hydrocodone , opioids . 6 . Had take investigational drug within 30 day prior Day 1 Visit currently enrol another investigational drug study . 7 . Had use monoamine oxidase inhibitor within 14 day prior Day 1 . 8 . Been take opioids 30 day prior Day 1 need take opioids study period 9 . Positive human immunodeficiency virus ( HIV ) . Healthy control subject must hepatitis C virus ( HCV ) positive , hepaticallyimpaired subject could HCV positive receiving treatment . 10 . History illicit substance abuse past 2 year history opioid abuse . Subjects current abuser alcohol must negative serum alcohol level Screening Day 1 . 11 . Positive quantitative urine drug screen illicit drug , nonprescribed controlled substance Screening . 12 . Had make plasma donation within 7 day prior Day 1 . 13 . Had make significant donation loss blood within 56 day prior Day 1 . 14 . Had take CYP2D6 and/or CYP3A4 inhibitor within 7 day prior Day 1 and/or CYP2D6 and/or CYP3A4 inducer within 21 day prior Day 1 .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>September 2014</verification_date>
</DOC>